Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial

MONT-SAINT-GUIBERT, Belgium, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T

Related Keywords

United States ,Mont Saint Guibert ,Waals Gewest ,Belgium ,New York ,Walloon Region ,Sara Zelkovic ,Charles Morris ,Merck Co Inc ,Exchange Commission ,Communications Investor Relations ,Merck Sharp Dohme ,Drug Administration ,Chief Medical Officer ,Merck Sharp ,Private Securities Litigation Reform Act ,Celyad Oncology ,Annual Report ,Media Contacts , ,